key: cord-1048008-l0k3eso9 authors: Antony, Anna; Connelly, Kathryn; De Silva, Thilinie; Eades, Laura; Tillett, William; Ayoub, Sally; Morand, Eric title: Perspectives of patients with rheumatic diseases in the early phase of COVID‐19 date: 2020-06-11 journal: Arthritis Care Res (Hoboken) DOI: 10.1002/acr.24347 sha: 630fc199e9596294a3289f51bec09749051fcb88 doc_id: 1048008 cord_uid: l0k3eso9 OBJECTIVE: To determine health perceptions of patients with rheumatic diseases in the early phase of the coronavirus disease 2019 (COVID‐19) pandemic. METHODS: Rheumatology patients at a single centre received via text message the national Rheumatology Association COVID‐19 information sheet and an invitation to participate in a de‐identified survey. Patient concerns regarding risks conferred by their rheumatological disease or medications, impact of receiving the information sheet on the likelihood of staying on medication, and acceptance of telehealth, were ascertained. RESULTS: 2,630 patients received the message and the survey response rate was 21% (n=550). Mean (±SD) age was 52 (±15.2) years and 75% were female. Participants’ highest ranked concern was that their medications would increase their severity of COVID‐19 (76.1%). The highest levels of concern were seen in patients on combination conventional synthetic disease‐modifying anti‐rheumatic drugs (csDMARDs) and/or a biologic/targeted synthetic disease‐modifying anti‐rheumatic drug (b/tsDMARD). There was no association between prednisolone dose and concern. While 63% of patients planned to continue their anti‐rheumatic medications, a further 30% were more likely to stay on their medications as a result of receiving the information. Telehealth was acceptable to 98.4% of patients, but 28.1% felt this was only appropriate while infection control measures were in place. CONCLUSION: Concerns regarding the risk of COVID‐19 among patients on anti‐rheumatic drugs are common. Proactive dissemination of information is needed to address misconceptions relating to medication risk, improve medication adherence and minimise the risk of flares. Telehealth is acceptable to a majority of patients during the COVID‐19 pandemic. The impact on the healthcare system of coronavirus disease 2019 (COVID-19) has been tempered in some regions by the early adoption of public health measures and extensive testing. [1] Healthcare systems have instituted major changes to achieve pandemic preparedness, such as deferment of elective surgery and non-urgent medical care, and widespread adoption of telehealth. Despite rapid developments in vaccines and therapeutics, infection control measures are likely to be in place in for a prolonged period of time. Evidence is lacking regarding the benefit of a proactive approach in communicating relevant advice regarding COVID-19 to patients to minimise preventable adverse outcomes. Integral to developing a strategy of communication is the need to understand the perceptions of patients with rheumatic diseases. The objectives of the current study were to investigate the concerns of rheumatology patients in regard to COVID-19, evaluate the potential impact of proactive dissemination of patient advice, and assess the acceptance of telehealth. Monash Health is a large tertiary hospital system in Australia. Patients of the rheumatology service with an appointment in the preceeding or subsequent 12 months were identified. Mobile telephone numbers of patients were extracted without identifying information. Patients were sent a text message identified as being from the Monash Health Department of Rheumatology, which directed them to the Australian Rheumatology Association (ARA) COVID-19 Information Sheet (version 3, 25 th of March 2020) and an invitation to complete an anonymous online survey. The information sheet describes the known prognostic factors for COVID-19, advises patients against stopping their medications unless they are unwell, reassures patients that there has been no data to date demonstrating increased mortality in rheumatology patients, and provides advice on next steps if patients were to become unwell. The information sheet also provided general public health advice and reinforced the importance of vaccinations. This article is protected by copyright. All rights reserved Baseline demographics collected included age, sex, rheumatological diagnosis, disease duration, current medications, current dose of prednisolone, and patient perception of disease control (visual analogue scale (VAS): 0-100; The VAS was annotated with anchoring instructions: 0: 'poorly controlled', 50: 'reasonable, but could be better', and 100: 'well-controlled'). Patients were asked if they believed that their rheumatological disease or medications increased their risk of contracting or becoming being more unwell with COVID-19. Patients who reported being concerned about their medications were asked to identify the medications of concern. The survey assessed whether patients had already obtained advice regarding their medications and if so, from what source. Patients were asked if they found the ARA patient information to be relevant and/or helpful, if receiving the information affected their intention to stay on their medications, and what information they would like included in future iterations. Acceptance of telehealth was assessed by asking patients about the situations in which a telehealth consultation was acceptable to them. Patients were able to tick as many options as applicable and suggest alternatives. Univariate binomial regression analysis was used to determine associations between exposure variables and patient perception regarding the COVID-19 risk associated with their rheumatological diagnosis and treatment. Exposure variables were age, sex, patient perception of disease control, disease duration, and diagnosis or treatment strategy. Exposure variables with a pvalue of <0.25 (pre-determined threshold) were included in multivariate analyses. Descriptive analysis was used to report concerns regarding specific medications, perceptions of telehealth, sources of information regarding COVID-19, and impact of the ARA patient information sheet. Statistical analyses were conducted using SPSS v.23.0 (IBM Corp., Armonk, NY, USA). Ethics approval was obtained from Monash Health (Ref: RES-20-0000-217Q). Of the eligible patients, 4% were not able to be contacted via text message as their mobile telephone numbers were not available. The survey response rate was 21% (n=550/2,630) with a mean completion time of 11 minutes. The mean (±SD) age of respondents was 52 (±15.2) years This article is protected by copyright. All rights reserved and 75% were female. The most common self-reported diagnoses were rheumatoid arthritis (RA) (29.7%) and systemic lupus erythematosus (SLE) (19.2%) ( to be concerned about being more unwell with COVID-19. These associations were attenuated in multivariate analyses (supplementary material). 55.7% of patients were concerned that their medications increased their risk of contracting COVID-19, while 76.1% were concerned that medications increased their risk of severity. 100% of patients on cyclophosphamide were concerned about medication-related risk, followed by 70% of patients on mycophenolate, 62% of patients on b/tsDMARDs, 57% of patients on azathioprine and 55% of patients on methotrexate. Patients were least concerned about hydroxychloroquine (20%) and NSAIDs (28%) ( Figure 1 ). In multivariate analysis, there was a small but significant negative association between age and patient concern that their medications could increase their risk of contracting or having severe combination csDMARDs or a b/tsDMARD were associated with increased concern regarding contracting COVID-19 while all treatments were associated with increased concern regarding severity of COVID-19 (Table 2 ). This article is protected by copyright. All rights reserved Sixty one percent of respondents (n=277) had already obtained patient information. The most common sources of information were the rheumatology department (31%), general practice (30%) or an internet search (17%). 9% of patients had obtained information from the Arthritis Australia website while 5% had obtained information from the Arthritis Foundation website. A majority of patients (92%) reported that they found the ARA patient information sheet helpful and elected to receive updated information via email (n=300) or text message (n=193). Most patients (63%) reported that the information sheet had not changed their existing plan to continue their medications, but 30% of patients reported that they were more likely to stay on their medications as a result of receiving the information. Additional information requested by patients included specific information regarding the impact of rheumatic disease, its activity, and immunosuppression (n=29), general information regarding COVID-19 (n=10), specific advice regarding work (n=4), support and reassurance regarding access to medications, particularly hydroxychloroquine (n=8), community services for immunosuppressed (n=4), advice regarding well-being practices while distancing (n=2) and management following exposure to or diagnosis with COVID-19 (n=2). The majority of patients (98.4%) considered the current use of telehealth to be appropriate. Factors that were important to patients in accepting telehealth were if their condition was well-controlled (60%), if their rheumatologist felt it was appropriate (56.2%), if the consultation was with a rheumatologist who knew their case well (55.1%) and if they were unwell and were unable to attend (34%). Additional reasons provided were work and family commitments, and transport limitations. A minority of patients felt that telehealth was only appropriate in times of strict infection control (28.1%) or that it was never appropriate (1.6%). Dealing with uncertainty is an important aspect of the practice of rheumatology, where patient uncertainty is common and associated with poorer health outcomes. [3] [4] [5] Our charge as clinicians is to minimise the experience of uncertainty in our patients, but our ability to do this has been challenged by the uncertainty surrounding the COVID-19 pandemic. Our aim in this study was to This article is protected by copyright. All rights reserved ascertain the perceptions and concerns of patients, in order to be able to better address them, thereby minimising patient uncertainty and possibly improving outcomes. The major findings were that concern regarding the impact of disease and/or treatment on COVID-19 risk and/or severity was common, that a pro-active intervention could increase adherence, and that telehealth was broadly acceptable. A significant proportion of patients were concerned that their underlying diagnosis increased their risk of contracting or becoming more unwell with COVID-19. There are robust data to support concerns that immune dysregulation in rheumatic diseases such as RA and SLE, particularly in high disease activity states, confers an increased infection risk. [6] [7] [8] [9] [10] In multivariate analysis, we did not identify any predictive factors for concern, highlighting the importance of outreach with information to all patients with rheumatic diseases. We found that 76% of respondents were concerned that their medications would increase their risk of becoming more unwell if they were to contract COVID-19. Exploring specific drugs, b/tsDMARDs, mycophenolate and cyclophosphamide were associated with the most concern. It could be conjectured that this heightened awareness reflects efforts taken by clinical staff to inform patients on these medications, but this was not studied here and there have been no previously published data on patient perceptions regarding infection risks associated with immunosuppression. In contrast, only 28% of patients were concerned regarding NSAIDs, which may reflect an understanding that these agents have not been shown to be associated with an increased risk of infection. Twenty percent were concerned regarding the infection risks posed by HCQ despite the well-publicised interest in this drug as a possible preventive or therapeutic for COVID-19. [11, 12] In multivariate analyses to identify patients who were most concerned about the risk posed by their immunosuppression, therapeutic regimens containing combination csDMARDs and b/tsDMARDs appeared to generate the most concern. This may reflect higher levels of clinician education provided to such patients. Such treatment may indicate a history of more severe disease and a higher risk of requiring rescue glucocorticoids in the event of a flare caused by drug cessation, underlining the importance of dissemination of information to these patients. Only 38% of patients on prednisolone were concerned regarding the risk it posed, despite its consistent associations with infection risk in observational studies. [7, 8, 10, 13] This may reflect the fact that 70% of patients on prednisolone were on doses of ≤5mg/day, although there was no relationship between prednisolone dose and patient concern. This article is protected by copyright. All rights reserved The exponential rise in COVID-19 cases in Australia began in March 2020, leading to the distribution of the ARA patient information sheet in late March 2020. [1] 61% of respondents had already obtained COVID-19 patient information, predominantly from their GP or rheumatology service. One third of patients reported that receiving the ARA information sheet made them more likely to continue their antirheumatic medication. We assessed the characteristics of patients who were more likely to stay on treatment as a result of education (31%) compared to patients who had already planned on stay on treatment (63%), but found no convincing predictors. The impact of the information sheet on adherence intentions was no different in patients who had already received information, irrespective of the source. We recorded patient suggestions for future iterations of an information sheet and found that patients largely wanted more specific information regarding the risks posed by their disease and treatment. Considered together with the other results, these findings highlight that the need for patient information amongst patients with rheumatic diseases is high. In regard to future iterations of patient information, patient concerns such as services available for immunosuppressed patients (e.g. pathology collection at home, delivery of medications, priority access to grocery shopping) and concerns regarding medication access were reported back to the ARA. In Australia, although telehealth is used to support remote and regional areas, its potential to improve the care of urban patients by complementing face-to-face services has been untapped. [14] This is largely due to limitations in funding models that subsidise only face-to-face care and the lack of technology infrastructure within clinics. The COVID-19 pandemic has resulted in huge increases telehealth consultations. There are limited data regarding the impact of telehealth on diagnostic accuracy and patient satisfaction outside of rural and regional settings, particularly in models of care that do not involve a primary care physician and in the assessment of new patients. [14, 15] We found that the overall acceptance of telehealth was high, but a quarter of patients considered that this was only appropriate while strict infection control measures were in place and nearly half did not feel it was appropriate if their condition was not well controlled or if their consultation was not with a clinician familiar with their case. This is the first descriptive study assessing the concerns of rheumatology patients in the era of COVID-19. Though a single-centre cross-sectional study, the sample size is large and it provides insights into patient perceptions in the early months of the pandemic. The key finding is that the need for information in patients with rheumatic diseases is high, particularly in regards to the risk posed by their diseases and medications. Whilst there is a high level of concern in patients Accepted Article This article is protected by copyright. All rights reserved on combination csDMARDs and b/tsDMARDs, concern regarding prednisolone is low and discordant with its risks. We ascertained a high level of acceptance of telehealth while strict infection controls are in place. Remaining research questions include capturing the actions patients have taken in regard to their immunosuppression and the impact of this on disease, the impact of a history of infections or co-morbidities on patient beliefs and behaviours, and the outcomes of patients who have had telehealth consultations. The major limitation of our study is response bias. The demographics and medications of all patients who received the invitation were not collected, and it is therefore difficult to hypothesize on the degree and direction of any response bias. We also did not collect data regarding the primary language, medical literacy, education status and socioeconomic status of participants, which may be relevant confounders or effect modifiers. The survey response rate does raise concerns regarding the method of information dissemination. Contributing factors may include the optional nature of the survey, lack of a reminder text, incorrect contact details, language or technological barriers, concerns regarding phishing, and lack of interest or relevance for patients with non-inflammatory conditions. A more expansive strategy using mail and email with translations of the information sheet where appropriate would be important in order to adequately reach all patients. This strategy was not feasible at the time this study was conducted given the urgency to disseminate patient information quickly. Patients with rheumatic diseases have significant concerns regarding their risk of contracting or being more unwell with COVID-19, misconceptions relating to medication risk are common and the need for information is high. The dissemination of patient information has the potential to avoid unnecessary patient-directed changes to therapy, which may minimise the risk of disease flare. There is overwhelming acceptance of telehealth substituting face-to-face consultations during the COVID-19 pandemic. (Abbreviations: 95% CI -95% Confidence Interval, b/tsDMARD -biologic or targeted synthetic disease-modifying anti-rheumatic drug, csDMARD -conventional synthetic disease-modifying anti-rheumatic drug, COVID-19 -Coronavirus Disease 2019, mg -milligram, SD -Standard Deviation; Missing data n=21 for concern regarding contracting COVID-19 and n=24 for concern regarding more severe disease with COVID-19) COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence Is Patient Uncertainty Associated with Outcomes in Systemic Lupus Erythematosus? Rheumatology (Oxford) What constitutes uncertainty in systemic lupus erythematosus and rheumatoid arthritis? Psychol Health Patient Uncertainty Questionnaire-Rheumatology (PUQ-R): development and validation of a new patient-reported outcome instrument for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in a mixed methods study. Health Qual Life Outcomes Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study The risk of hospitalized infection in patients with rheumatoid arthritis High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro Accepted Article This article is protected by copyright. All rights reserved 12 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Infection Risk and Safety of Corticosteroid Use Satisfaction with rural rheumatology telemedicine service Telerheumatology--diagnostic accuracy and acceptability to patient, specialist, and general practitioner Accepted Article This article is protected by copyright. All rights reserved